Tekmira
The study is being conducted in Sierra Leone by the University of Oxford.
The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.
The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.
The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.
Following the transaction, hepatitis B will become Tekmira's top priority, although the company said it will continue work on its other RNAi programs.
Dec 22, 2014
Nov 18, 2014
Nov 10, 2014
Nov 6, 2014
Oct 23, 2014
Oct 9, 2014
Sep 25, 2014
Aug 28, 2014
Aug 28, 2014
Aug 21, 2014
Aug 14, 2014
Aug 14, 2014
Aug 14, 2014
Jul 24, 2014
Jul 17, 2014
Jul 10, 2014
Jul 3, 2014
Jun 19, 2014
May 29, 2014
May 22, 2014